



Wanbury Limited

Regd. Office : BSEL Tech Park, B-wing
10th Floor, Sector-30 A,
Opp. Vashi Railway Station,
Vashi Navi Mumbai 400 703
Maharashtra, INDIA
Tel. : +91-22-6794 2222
+91-22-7196 3222
CIN L51900MH1988PLC048455
Email : info@wanbury.com
Website : www.wanbury.com

Wanbury Limited					
Statement of Standalone Uaudited Financial Results for the Quarter ended 30 June 2024					
Sr. No.	Particulars	Quarter ended		Year ended	
		30/06/2024	31/03/2024	30/06/2023	31/03/2024
		Unaudited	Audited	Unaudited	Audited
1	Income:				
	(a) Revenue from operations	13,110.82	13,940.56	14,628.54	57,564.98
	(b) Other income	94.46	92.52	61.66	299.00
	Total Income	13,205.28	14,033.08	14,690.20	57,863.98
2	Expenses:				
	(a) Cost of materials consumed	6,419.91	6,687.21	8,274.69	28,921.83
	(b) Purchase of stock-in-trade	327.55	397.56	316.82	1,730.34
	(c) Changes in inventories of finished goods, stock in trade and work-in-progress	(121.98)	(42.22)	(88.92)	(389.11)
	(d) Employee benefits expense	2,515.16	2,013.58	2,108.30	8,692.43
	(e) Finance costs	759.26	746.04	578.94	2,918.11
	(f) Depreciation and amortisation expense	328.87	327.97	318.47	1,303.06
	(g) Other expenses	2,872.77	3,068.08	2,682.83	11,609.27
	Total Expenses	13,101.54	13,198.22	14,191.13	54,785.93
3	Profit/(Loss) before tax	103.74	834.86	499.07	3,078.05
4	Tax expenses:				
	(a) Current Tax	-	-	-	-
	(b) Deferred Tax (Net)	-	27.21	30.24	38.10
5	Profit/(Loss) after tax	103.74	807.65	468.83	3,039.95
6	Other comprehensive Income / (Loss)				
	Items that will not be reclassified subsequently to profit or loss	(27.26)	(74.13)	(96.93)	(109.04)
	Income tax relating to items that will not be reclassified to profit or loss	-	27.21	30.24	38.10
	Other comprehensive Income / (Loss) net of tax	(27.26)	(46.92)	(66.69)	(70.94)
7	Total comprehensive Income / (Loss)	76.48	760.73	402.14	2,969.01
8	Paid up Equity Share Capital (Face Value of ₹ 10 each)	3,274.55	3,274.55	3,270.55	3,274.55
9	Other equity				(480.41)
10	Earnings/(Loss) per share of ₹ 10 each				
	(1) Basic - Before Exceptional Items in ₹	0.32	2.47	1.43	9.29
	(2) Basic - After Exceptional Items in ₹	0.32	2.47	1.43	9.29
	(1) Diluted - Before Exceptional Items in ₹	0.31	2.37	1.43	9.18
	(2) Diluted - After Exceptional Items in ₹	0.31	2.37	1.43	9.18

Notes

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at the meeting held on 12 August 2024.
- These results are prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind 34") prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles, practices and policies generally accepted in India.
- The Company has only one segment of activity namely "Pharmaceuticals", with two USFDA manufacturing facilities, at Tanuku, Andhra Pradesh and Patalganga, Maharashtra.

Company has successfully cleared USFDA inspection at the Patalganga facility with zero-483 observations during this quarter.
- The manufacturing facility at Patalganga was under up-gradation and renovation for part of the current quarter and the same has not been utilised to the optimum levels, hence impacting revenues and profitability for the quarter.
- The figures for the fourth quarter ended 31 March 2024 in the above financial results are the balancing figures between audited figures for the full financial year and the year to date unaudited figures published up to the nine months ended 31 December 2023 which were subjected to limited review.
- The figures of previous periods/year have been re-grouped / re-classified wherever necessary, to correspond with figures of current period.

Place : Mumbai
Date: 12 August 2024



For Wanbury Ltd.

K. Chandran
Vice Chairman
(DIN : 00005868)



Independent Auditor's Review Report on Review of Interim Consolidated Financial Results

To

The Board of Directors of
WANBURY LIMITED

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Wanbury Limited** (hereinafter referred to as the "the Parent" or "the Company") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended 30 June 2024 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors in their meeting held on 12 August 2024, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.
5. The Statement includes the results of the Parent and the following entities:
Subsidiaries:
 - a) Wanbury Holding B.V
 - b) Ningxia Wanbury Fine Chemicals Company Limited
 - c) Wanbury Global FZE



6. Material Uncertainty Related to Going Concern

During the previous financial year, the Group has made profit and its net worth has become positive. However, the Group's current liabilities exceed its current assets resulting in delayed payments and overdue amounts to creditors. The Group is taking appropriate steps to raise adequate funds and restructure its borrowings to address the concerns. Hence, the consolidated financial results have been prepared on "going concern" basis.

Our conclusion on the Statement is not modified in respect of this matter.

7. Attention is drawn to the fact that the figures for the three months ended 31 March 2024 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
8. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matters

9. The Statement includes the interim financial results of three subsidiaries which have not been reviewed, whose interim financial results reflect total revenue, total net profit / loss after tax and total comprehensive income each Rs Nil, for the quarter ended 30 June 2024 respectively, as considered in the Statement. According to the information and explanations given to us, these unaudited interim financial results, which have been approved and furnished to us by the management, are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

FOR V. PAREKH & ASSOCIATES
CHARTERED ACCOUNTANTS
FIRM REGN. NO. 107488W



Rasesh V. Parekh
RASESH V. PAREKH – PARTNER
MEMBERSHIP NO. 38615

UDIN: 24038615BKBF06256

PLACE : MUMBAI
DATED: 12TH AUGUST 2024



Wanbury Limited

Regd. Office : BSEL Tech Park, B-wing
10th Floor, Sector-30 A,
Opp. Vashi Railway Station,
Vashi Navi Mumbai 400 703
Maharashtra, INDIA
Tel. : +91-22-6794 2222
+91-22-7196 3222
CIN L51900MH1988PLC048455
Email : info@wanbury.com
Website : www.wanbury.com

Wanbury Limited					
Statement of Consolidated Unaudited Financial Results for the Quarter ended 30 June 2024					
Sr.No.	Particulars	Quarter ended			Year ended
		30/06/2024	31/03/2024	30/06/2023	31/03/2024
		Unaudited	Audited	Unaudited	Audited
1	Income:				
	(a) Revenue from operations	13,110.82	13,940.56	14,628.54	57,564.98
	(b) Other income	94.46	92.52	61.66	299.00
	Total Income	13,205.28	14,033.08	14,690.20	57,863.98
2	Expenses:				
	(a) Cost of materials consumed	6,419.91	6,687.21	8,274.69	28,921.83
	(b) Purchase of stock-in-trade	327.55	397.56	316.82	1,730.34
	(c) Changes in inventories of finished goods, work-in-progress and stock in trade	(121.98)	(42.22)	(88.92)	(389.11)
	(d) Employee benefits expense	2,515.16	2,013.58	2,108.30	8,692.43
	(e) Finance costs	759.26	746.04	578.94	2,918.11
	(f) Depreciation and amortisation expense	328.87	327.97	318.47	1,303.06
	(g) Other expenses	2,872.77	3,068.08	2,682.83	11,609.27
	Total Expenses	13,101.54	13,198.22	14,191.13	54,785.93
	Profit/(Loss) before exceptional items and tax	103.74	834.86	499.07	3,078.05
	Exceptional Items (Net)	-	2,555.68	-	2,555.68
3	Profit/(loss) before tax	103.74	3,390.54	499.07	5,633.73
4	Tax expenses :				
	(a) Current Tax	-	-	-	-
	(b) Deferred Tax(Net)	-	27.21	30.24	38.10
5	Profit/(Loss) after tax	103.74	3,363.33	468.83	5,595.63
6	Other comprehensive Income / (loss)				
	Items that will not be reclassified subsequently to profit or loss:				
	Income tax relating to items that will not be reclassified to profit or loss	-	27.21	30.24	38.10
	(b) Items that will be reclassified to profit or loss:				
	Exchange difference on translation of foreign operations	-	(5.59)	1.08	0.03
	Other comprehensive Income / (Loss) net of tax	(27.26)	(52.51)	(65.61)	(70.91)
7	Total comprehensive Income / (Loss)	76.48	3,310.82	403.22	5,524.72
8	Paid up Equity Share Capital (Face Value of ₹ 10 each)	3,274.55	3,274.55	3,270.55	3,274.55
9	Other Equity				(480.41)
10	Earnings/(Loss) per share of ₹ 10 each- Not annualised				
	(1) Basic - Before Exceptional Items in ₹	0.32	2.47	1.43	9.29
	(2) Basic - After Exceptional Items in ₹	0.32	10.28	1.43	17.10
	(3) Diluted - Before Exceptional Items in ₹	0.31	2.37	1.43	9.18
	(4) Diluted - After Exceptional Items in ₹	0.31	10.08	1.43	16.89

Notes

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at the meeting held on 12 August 2024.
- The consolidated financial results of Wanbury Limited or the Company or the Holding Company and its wholly owned subsidiaries (together referred to as "the Group") have been prepared as per Ind AS 110 on Consolidated Financial Statements. There is no minority interest.
- These results are prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles, practices and policies generally accepted in India.
- The Group has only one segment of activity namely "Pharmaceuticals", with two USFDA manufacturing facilities, at Tanuku, Andhra Pradesh and Patalganga, Maharashtra.
Group has successfully cleared USFDA inspection at the Patalganga facility with zero-483 observations during this quarter.
- The manufacturing facility at Patalganga was under up-gradation and renovation for part of the current quarter and the same has not been utilised to the optimum levels, hence impacting revenues and profitability for the quarter.
- The figures for the fourth quarter ended 31 March 2024 in the above financial results are the balancing figures between audited figures for the full financial year and the year to date unaudited figures published up to the nine months ended 31 December 2023 which were subjected to limited review.
- The figures of previous periods/year have been re-grouped / re-classified wherever necessary, to correspond with figures of the current period.



Place : Mumbai
Date: 12 August 2024

For Wanbury Ltd.

K. Chandran
Vice Chairman
(DIN : 00005868)

